Yoshiki Miyata

Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells.

Takashi Sato, Leona Koike, Yoshiki Miyata et al. · PubMed · 2002 · 155 citations

Medicine, Oncology, Pharmacology +15

Regulation of adipocytokine secretion and adipocyte hypertrophy by polymethoxyflavonoids, nobiletin and tangeretin

Yoshiki Miyata, Haruyuki Tanaka, Arata Shimada et al. · Life Sciences · 2011 · 105 citations

Life Sciences, Biochemistry, Pharmacology +13

A citrus polymethoxyflavonoid, nobiletin, is a novel MEK inhibitor that exhibits antitumor metastasis in human fibrosarcoma HT-1080 cells

Yoshiki Miyata, Takashi Sato, Keisuke Imada et al. · Biochemical and Biophysical Research Communications · 2007 · 88 citations

Medicine, Oncology, Pharmacology +9

Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin.

Yoshiki Miyata, Takashi Sato, Masamichi Yano et al. · PubMed · 2004 · 56 citations

Medicine, Oncology, Pharmacology +14

Activation of protein kinase C βII/ε-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin

Yoshiki Miyata, Takashi Sato, Masamichi Yano et al. · Molecular Cancer Therapeutics · 2004 · 51 citations · Full text

Medicine, Oncology, Pharmacology +14